A5068770341- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Cardiac Arrhythmias and Treatments
- Multiple Myeloma Research and Treatments
- Cardiac Imaging and Diagnostics
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Myasthenia Gravis and Thymoma
- Cardiac tumors and thrombi
- Cardiovascular Syncope and Autonomic Disorders
- Atrial Fibrillation Management and Outcomes
- Pericarditis and Cardiac Tamponade
- Spine and Intervertebral Disc Pathology
- Venous Thromboembolism Diagnosis and Management
- Central Venous Catheters and Hemodialysis
- Protein Degradation and Inhibitors
- Cardiac and Coronary Surgery Techniques
- Medieval European Literature and History
- Biochemical Acid Research Studies
- PI3K/AKT/mTOR signaling in cancer
- HIV/AIDS drug development and treatment
- Neurological Disorders and Treatments
- Bone health and treatments
Ospedale degli Infermi
2021-2024
Ospedale Infermi di Rimini
2011-2021
Ospedale degli Infermi
2021
PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted postinduction approach in patients follicular lymphoma who responded to induction immunochemotherapy. METHODS randomly assigned treatment-naïve, advanced-stage, high-tumor burden receive standard RM or on the basis metabolic response and molecular assessment minimal residual disease (MRD). The experimental arm used three types therapies: for complete (CMR) MRD-negative patients, observation; CMR MRD-positive...
Diagnosis and monitoring of multiple myeloma (MM) related conditions are usually carried out by means serum urine protein electrophoresis immunofixation. In the early 2000s, an assay aimed at evaluating free light chains (sFLCs) was made available subsequently tested in different plasma cell disorders. Several reports have demonstrated usefulness for diagnosis oligosecretory MM, nonsecretory Bence Jones amyloid light-chain amyloidosis. Furthermore, a prognostic role abnormal sFLC κ/λ ratio...
Vertebral fractures occur in over 60% of newly diagnosed multiple myeloma (MM) patients and can cause pain, disability poor quality life. Antimyeloma therapy lead to symptoms improvement, but these effects take time be perceived. Application radiotherapy prior peripheral blood stem cells (PBSC) mobilisation impair cell collection. Percutaneous vertebroplasty has been proposed as a suitable option rapidly relieve bone pain from vertebral MM patients, but, little is known about the this...
In chronic-phase chronic myeloid leukemia (CML), tyrosine kinase inhibitors (TKIs) are the standard of care, and treatment-free remission (TFR) following achievement a stable deep molecular response (DMR) has become, alongside survival, primary goal for virtually all patients. The GIMEMA CML working party recently suggested that possibility achieving TFR cannot be denied to any patient, proposed specific treatment policies according patient's age risk. However, other international...
Autologous stem cell transplantation is considered the standard of care for multiple myeloma patients aged < 65 years with no relevant comorbidities. The addition drugs acting both on bone marrow microenvironment and neoplastic plasma cells has significantly increased proportion achieving a complete remission after induction therapy, these results are mantained high-dose melphalan, leading to prolonged disease control. Studies being carried out in order evaluate whether short term...
Renal failure (RF) occurs in approximately 20-30% of multiple myeloma (MM) patients at diagnosis and more than 50% with advanced disease. The pathogenesis RF is related to the production monoclonal light chains that can damage either tubule (myeloma kidney) or glomeruli (light chain deposition disease amyloid light-chain amyloidosis). In past, prognosis MM was considered poor due limited number effective non-nephrotoxic drugs were available. At present, novel acting both on clone bone marrow...
Background: Pregnancy (P) might trigger or exacerbate a pre existing Immune thrombocytopenia (ITP). A substantial risk of maternal bleeding at delivery (D), side effects ITP treatment (tx), the neonate and worsening disease lasting after D are possible consequences related to P. Specific evidence-based guidelines lacking in this setting suggestions about management derived from non-pregnant population. Moreover data efficacy safety tx limited P, especially for thrombopoietin receptor...